Skip to main content
TipRanks
Go Ultimate75% OFF

Insulet (PODD) AI Stock Analysis

1,109 Followers
PODD

Insulet

(NASDAQ:PODD)

Select Model
Rating:70Outperform
Price Target:$154.00â–²(10.02% Upside)
Action:reiterated
Date:11/05/26

The score is driven primarily by strong profitability and margin expansion momentum reinforced by a positive earnings call and supportive 2026 guidance. Offsetting factors are the sharp recent decline in TTM cash flow and weak cash conversion, plus an overbought technical setup and a growth-leaning valuation without dividend support.

Positive Factors
Recurring Revenue and Customer GrowthOmnipod’s recurring, disposable-pod model converts a growing installed base into repeat revenue, supporting visibility beyond individual device sales. More than 20% customer growth and consistent consumption indicate expanding adoption and a durable foundation for continued revenue generation.
Negative Factors
Weak Recent Cash ConversionRecent cash generation has not kept pace with reported earnings, creating a meaningful quality and execution concern despite strong profitability. Lower free cash flow can reduce flexibility for investment, debt management, and capital returns if the weaker conversion persists.

Insulet Key Performance Indicators (KPIs)

Revenue by SegmentProvides insight into which business segments are driving sales, highlighting areas of strength and potential growth within the company's operations.

$0.00$200.00M$400.00M$600.00M$800.00MMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

Omnipod is the growth engine—U.S. and international sales have scaled rapidly, with international accelerating faster and taking a larger share while Drug Delivery remains negligible. Management confirmed international strength (raised guidance to ~30–32%) but trimmed U.S. outlook due to type‑2 onboarding/first‑90‑day retention issues and is rolling out customer‑care, sampling and sales fixes. Going forward, international execution will drive upside, but U.S. retention remediation (new customer starts, 90‑day utilization) is the key risk to watch.

Data provided by:The Fly

Insulet (PODD) vs. SPDR S&P 500 ETF (SPY)

-80%-60%-40%-20%0%20%40%PODD-57.73%SPY+13.11%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$9.71B
Dividend Yield
―
Average Volume (3M)
1.57M
Price to Earnings (P/E)
22.8
Beta (1Y)
0.19
Revenue Growth
26.46%
EPS Growth
75.56%
Country
US
Employees
5,400
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Insulet Business Overview & Revenue Model

Company Description

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin de...

How the Company Makes Money

Insulet primarily makes money by selling its Omnipod insulin delivery system through a recurring, disposable-based model. The largest revenue driver is the ongoing sale of Omnipod pods—single-use, wearable, tubeless insulin delivery devices that pati...

Insulet Earnings Call Summary

Earnings Call Date:Nov 04, 2026(Q3-2026)|% Change Since:-9.61%|Next Earnings Date:Feb 25, 2027
Earnings Call SentimentPositive

The call was strongly positive overall. Insulet reported nearly 20% third-quarter revenue growth, more than 20% customer-base growth, record gross margin, substantial operating-margin expansion, and 60% adjusted EPS growth. The company also raised its confidence in the high end of 2026 guidance, advanced multiple product and commercial initiatives, and announced increased share repurchase capacity. The main concerns were softer new customer starts, type 2 retention challenges, expected competitive share pressure, and a more conservative 2027 outlook with meaningful moderation in international growth.

Positive Updates

Strong Third-Quarter Revenue Growth
Third-quarter revenue was $842 million, up 19.2% on a reported basis and 19.6% on a constant-currency basis. U.S. revenue grew 14.7%, while international revenue grew 31.7% reported and 33% in constant currency.

Negative Updates

New Customer Starts Were Soft in the Quarter
Global new customer starts grew low single digits versus the prior-year period, while U.S. new customer starts were flat. Year-to-date global new customer starts had grown low double digits.

Company Guidance

For full year 2026, Insulet expects constant currency revenue growth of 21% to 22% for total company and 21.5% to 22.5% for total Omnipod, with foreign exchange expected to positively contribute approximately a 100-basis-point to Omnipod and total company growth; US Omnipod revenue growth is expected at 17.5% to 18.5%, international Omnipod revenue growth at 32% to 33%, and fourth quarter total company, total Omnipod, US Omnipod, and international Omnipod revenue growth at 13.5% to 17%, 13% to 16.5%, 10% to 13.5%, and 21% to 24%, respectively, with foreign exchange expected to be a headwind of approximately 50 basis points to international growth. Insulet expects approximately 150 basis points of adjusted operating margin expansion, net interest and other expense of $40 million to $45 million, a non-GAAP tax rate of 20% to 20.5%, approximately 70 million shares outstanding, adjusted EPS growth of more than 30%, and free cash flow of approximately $275 million in 2026. For 2027, the company expects total company growth to be modestly below the mid teens framework, plans to guide toward the lower end of the prior 9% to 14% framework for the US, and expects international growth to moderate meaningfully from 2026; formal guidance is expected in February.

Insulet Financial Statement Overview

Summary

Strong profitability and margin profile (healthy net and EBIT margins) alongside meaningful leverage improvement support a solid fundamental base. However, the latest TTM cash-flow deterioration and weak cash conversion versus net income are a material risk, reducing overall financial consistency despite strong income-statement performance.

Income Statement

86Very Positive

Balance Sheet

74Positive

Cash Flow

46Neutral
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue3.19B2.71B2.07B1.70B1.31B1.10B
Gross Profit2.29B1.94B1.45B1.16B805.60M752.10M
EBITDA686.30M509.60M423.70M323.60M109.00M139.60M
Net Income428.80M247.10M418.30M206.30M4.60M16.80M
Balance Sheet
Total Assets3.42B3.19B3.09B2.59B2.25B2.05B
Cash, Cash Equivalents and Short-Term Investments584.40M716.10M953.40M704.20M674.70M791.60M
Total Debt962.10M1.05B1.42B1.45B1.43B1.29B
Total Liabilities1.84B1.68B1.88B1.86B1.77B1.49B
Stockholders Equity1.58B1.52B1.21B732.70M476.40M556.30M
Cash Flow
Free Cash Flow260.00M377.70M305.40M70.10M-38.30M-190.80M
Operating Cash Flow509.00M569.30M430.30M145.70M119.00M-68.10M
Investing Cash Flow-284.80M-222.70M-146.20M-119.40M-191.10M-82.70M
Financing Cash Flow-394.40M-595.30M-28.10M-13.60M-40.30M40.70M

Insulet Technical Analysis

Technical Analysis SentimentNegative
Last Price139.98

Price Trends

50DMA142.20Negative
100DMA147.90Negative
200DMA171.04Negative

Market Momentum

MACD0.65Positive
RSI42.00Neutral
STOCH7.85Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PODD, the sentiment is Negative. The current price of 139.98 is below the 20-day moving average (MA) of 150.19, below the 50-day MA of 142.20, and below the 200-day MA of 171.04, indicating a bearish trend. The MACD of 0.65 indicates Positive momentum. The RSI at 42.00 is Neutral, neither overbought nor oversold. The STOCH value of 7.85 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PODD.

Insulet Risk Analysis

Insulet disclosed 36 risk factors in its most recent earnings report. Insulet reported the most risks in the "Legal & Regulatory" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

3 New Risks
1.Expansion of U.S. tariffs could have a material adverse effect on our financial results.Q4, 2025
2.The rapidly-changing technical and regulatory environment and our AI-related activities may have an adverse effect on our business.Q4, 2024
3.Changes in tax laws or exposures to additional tax liabilities could negatively impact our operating results.Q4, 2024

Insulet Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

PODD against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
MDTMDT81Outperform$130.88B24.6910.60%2.84%9.77%12.28%
DXCMDXCM73Outperform$30.78B31.8636.50%―13.03%40.88%
PODDPODD70Outperform$9.71B22.7629.48%―26.46%75.56%
ABTABT67Neutral$181.35B38.709.11%2.41%10.00%-66.06%
TNDMTNDM65Neutral$1.19B-23.72-35.61%―6.73%76.54%
BBNXBBNX54Neutral$779.08M-7.66-27.33%―43.69%-3.00%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-50%0%50%PODDABTDXCMMDTTNDMBBNXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
PODD and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
PODDInsulet139.98-172.91-55.26%
ABTAbbott Laboratories104.48-16.48-13.63%
DXCMDexcom82.5224.1041.25%
MDTMedtronic100.724.564.74%
TNDMTandem Diabetes Care17.05-2.45-12.56%
BBNXBeta Bionics, Inc.14.33-14.07-49.54%

Insulet Corporate Events

Stock BuybackFinancial DisclosuresProduct-Related Announcements

Insulet Reports Strong Third-Quarter Growth and Margin Expansion

Positive
Nov 4, 2026

On November 4, 2026, Insulet reported third-quarter revenue of $842.0 million, up 19.2% year over year, with Omnipod revenue rising 19.7%. Operating income increased to $189.8 million, net income reached $141.1 million, and adjusted diluted earnings...

Business Operations and StrategyPrivate Placements and Financing

Insulet Amends Credit Facilities, Expands Revolving Commitments

Positive
Sep 21, 2026

On September 21, 2026, Insulet Corporation amended its existing credit agreement, replacing $475 million of outstanding term loans with an equal amount of new term loans at lower interest rate margins. The new loans, issued at par, along with cash on...

Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and Compliance

Insulet Introduces New Executive Deferred Compensation Plan

Positive
Sep 16, 2026

On September 14, 2026, Insulet’s Talent and Compensation Committee approved a Nonqualified Deferred Compensation Plan, effective January 1, 2027, for a select group of management and highly compensated employees under ERISA, including named executive...

Executive/Board Changes

Insulet announces upcoming director resignations amid transitions

Neutral
Sep 10, 2026

On September 3, 2026, longtime director and former chairman Timothy J. Scannell stepped down from Insulet’s board for health reasons, ending a 12-year tenure that included seven years as chairman during a period of substantial growth and advancement...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 05, 2026